Dianthus Therapeutics, Inc.
DNTH
$78.86
-$0.04-0.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -126.55% | -46.04% | -79.64% | -114.66% | -169.24% |
| Total Depreciation and Amortization | 24.36% | -14.66% | -10.81% | 24.30% | -24.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 263.43% | 173.15% | 71.18% | 124.85% | 573.37% |
| Change in Net Operating Assets | 3,057.82% | 9.85% | 956.06% | 40.97% | 73.51% |
| Cash from Operations | -71.20% | -43.67% | -64.45% | -84.93% | -131.52% |
| Capital Expenditure | -345.16% | 80.00% | -170.59% | 25.00% | -210.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 261.80% | 22.39% | 2,133.64% | 370.65% | -180.53% |
| Cash from Investing | 260.98% | 22.40% | 2,162.19% | 368.64% | -180.56% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -87.21% | 92,698.99% | 1,108.51% | -99.93% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -87.69% | 92,640.88% | 125.87% | -99.93% | 915.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 54.98% | 115.23% | 120.06% | -106.42% | 56.41% |